LEVOLEUCOVORIN CALCIUM

Post-LOE

Novartis

ANDAINTRAVENOUSSOLUTION

Approved

Mar 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

LEVOLEUCOVORIN CALCIUM by Novartis is high-dose methotrexate therapy levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Approved for pernicious anemia, megaloblastic anemia secondary to lack of vitamin b 12, because of the risk of progression of neurologic manifestations despite hematologic remission. First approved in 2015.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

High-Dose Methotrexate Therapy Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “one-carbon” moieties.…

Indications (3)

pernicious anemia

Worked on LEVOLEUCOVORIN CALCIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.